Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: CD as drug

November 19, 2026 CD as API / CD derivatives / Pharma applications

Cyclodextrins Target Inflammatory Foam Cells in Multiple Sclerosis Lesions

Foamy, lipid-laden macrophages are found in multiple sclerosis (MS) lesions, resulting from excessive phagocytosis of myelin debris following demyelination. These

Continue reading

November 16, 2026 CD as API / CD derivatives / Pharma applications

FDA Clears Cyclarity’s UDP-003 Trial for Heart Disease

Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging,

Continue reading

March 31, 2026 CD as API / CD derivatives / Drug delivery / Pharma applications

Phosphorylated Beta-cyclodextrin as a New Bone-Targeting Drug Delivery System Could Change the Treatment of Osteoporosis and Other Bone Diseases

Researchers in Japan have developed a promising new drug delivery platform that not only carries medicines directly to bone, but

Continue reading

March 19, 2026 CD as API / CD derivatives / Pharma applications

Evaluation of the Potential Therapeutic Effects of HPβCD and SBEβCD in a Mouse Model of Acute Ulcerative Colitis

A Nanjing, China based research group designed a tailored investigation [1] based on a surprising previous study [2]. In they

Continue reading

March 16, 2026 CD as API / Pharma applications

HPαCD Therapy: A Breakthrough for Krabbe Disease Treatment

Several North-American Universities worked together to find hydroxzpropyl-alpha-cyclodextrin(HPaCD) for the treatment of Krabbe disease. The deficiency of β-galactosylceramidase causes a

Continue reading

February 19, 2026 CD as API / Drug delivery / Pharma applications

Enhancing the Water Solubility and Efficacy of Anticancer Drugs Using Hydroxypropyl-β-Cyclodextrin

Previous studies have demonstrated that the solubility and biocompatibility of poorly water-soluble anti-cancer agents can be improved by complexation with

Continue reading

December 19, 2022 CD as API / Pharma applications

HPβ-CD as affordable antiviral to treat coronavirus infection

In a recent study posted to the bioRxiv* preprint server, researchers identified β-cyclodextrins (β-CDs) as a safe and cost-effective drug

Continue reading

May 4, 2022 CD as API / CD derivatives / Drug delivery / Pharma applications

Implementation of water-soluble cyclodextrin-based polymers in biomedical applications: how far are we?

Cyclodextrin-based polymers can be prepared starting from the naturally occurring monomers following green and low-cost procedures. They can be selectively

Continue reading

January 12, 2022 CD as API / Pharma applications

Cyclodextrin for treating lymphedema

A recent patent application of NATIONAL UNIVERSITY OF SINGAPORE claims for the treatment of lymphedema by using empty cyclodextrin (beta-cyclodextrin

Continue reading

October 15, 2021 Events

Statistics of registered participants at the CycloLab’s webinar on “Cyclodextrins as active ingredients in the 21st century”

The webinar was a great success with altogether 793 registered participants from 66 countries. The highest interest was shown by

Continue reading

Posts pagination

1 2 Next Posts»

Recent Posts

  • HUPHAR 2027
  • Cyclodextrins Target Inflammatory Foam Cells in Multiple Sclerosis Lesions
  • FDA Approves LEMBAZ for Infantile-Onset Niemann-Pick Disease
  • HPBCD beads for drug delivery
  • FDA Clears Cyclarity’s UDP-003 Trial for Heart Disease

Tags

alpha-CD atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Sugammadex Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (28)
  • Analysis (75)
  • CD as API (364)
  • CD derivatives (447)
  • Cosmetics and toilettry (55)
  • Diagnosis (15)
  • Drug delivery (835)
  • E-ducation (64)
  • Environmental (144)
  • Events (244)
  • Food (239)
  • Gene delivery (22)
  • Household products (6)
  • In Hungarian (4)
  • Life sciences (46)
  • Non-pharma applications (429)
  • Other industrial use (115)
  • Pharma applications (1,247)
  • Supramolecular systems (45)
  • Uncategorized (178)

Top Posts

  • Cyclodextrins Target Inflammatory Foam Cells in Multiple Sclerosis Lesions
  • FDA Approves LEMBAZ for Infantile-Onset Niemann-Pick Disease
  • HUPHAR 2027
  • MIT scientists filed patent for HPBCD treatment in Alzheimer's disease
  • HPBCD beads for drug delivery
  • Special Issue of the journal Materials "Cyclodextrin-Based Nanomaterials: Synthesis, Properties, and Applications”
  • Honoring Professor Tsuneji Nagai
  • FDA Clears Cyclarity’s UDP-003 Trial for Heart Disease
  • Cyclodextrins without holes are reality
  • Targeted Codelivery of Doxorubicin and Carvacrol Nanogels

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,472 other subscribers
Loading Comments...